See more : Gelesis Holdings, Inc. (GLS) Income Statement Analysis – Financial Results
Complete financial analysis of ClearPoint Neuro, Inc. (CLPT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ClearPoint Neuro, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Abingdon Health Plc (ABDXF) Income Statement Analysis – Financial Results
- Illumina, Inc. (ILMN) Income Statement Analysis – Financial Results
- Hainan Airport Infrastructure Co., Ltd (600515.SS) Income Statement Analysis – Financial Results
- STI Group, Inc. (STUO) Income Statement Analysis – Financial Results
- ChromoGenics AB (CHRO.ST) Income Statement Analysis – Financial Results
ClearPoint Neuro, Inc. (CLPT)
About ClearPoint Neuro, Inc.
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system for the insertion of deep brain stimulation electrodes and biopsy needles, and the infusion of pharmaceuticals and laser catheters into the brain; and ClearPoint Neuro Navigation System, an MRI suite. It has license and collaboration agreements with Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and University of California and San Francisco. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 23.96M | 20.55M | 16.30M | 12.83M | 11.22M | 7.35M | 7.38M | 5.75M | 4.59M | 3.60M | 3.93M | 5.06M | 3.82M | 2.67M |
| Cost of Revenue | 10.34M | 7.02M | 5.01M | 3.71M | 3.83M | 2.43M | 2.90M | 2.64M | 1.99M | 1.93M | 1.42M | 555.70K | 656.41K | 16.31K |
| Gross Profit | 13.61M | 13.53M | 11.29M | 9.12M | 7.38M | 4.92M | 4.48M | 3.11M | 2.61M | 1.68M | 2.51M | 4.50M | 3.16M | 2.65M |
| Gross Profit Ratio | 56.83% | 65.84% | 69.27% | 71.09% | 65.83% | 66.91% | 60.72% | 54.03% | 56.74% | 46.53% | 63.84% | 89.01% | 82.81% | 99.39% |
| Research & Development | 11.71M | 10.89M | 8.99M | 4.69M | 2.92M | 2.31M | 2.81M | 2.63M | 1.96M | 3.30M | 2.92M | 1.60M | 4.25M | 5.68M |
| General & Administrative | 11.76M | 9.61M | 8.76M | 5.27M | 4.30M | 4.33M | 4.05M | 4.19M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 12.60M | 9.36M | 6.92M | 5.38M | 4.76M | 3.53M | 3.96M | 3.78M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 24.35M | 18.97M | 15.68M | 10.65M | 9.06M | 7.86M | 8.00M | 7.97M | 8.37M | 8.04M | 7.06M | 6.03M | 4.83M | 4.70M |
| Other Expenses | 0.00 | -22.00K | -63.00K | 882.00K | 9.05K | 364.00 | 16.68K | 216.08K | 230.88K | 1.80M | 863.79K | 2.80K | 104.85K | 413.62K |
| Operating Expenses | 36.06M | 29.86M | 24.67M | 15.34M | 11.98M | 10.17M | 10.82M | 10.60M | 10.33M | 11.34M | 9.98M | 7.63M | 9.08M | 10.38M |
| Cost & Expenses | 46.40M | 36.88M | 29.67M | 19.05M | 15.81M | 12.60M | 13.72M | 13.24M | 12.32M | 13.26M | 11.41M | 8.19M | 9.74M | 10.40M |
| Interest Income | 386.00K | 81.00K | 973.00K | 1.44M | 955.00K | 0.00 | 0.00 | 8.81K | 16.46K | 11.62K | 24.54K | 14.15K | 3.48K | 10.40K |
| Interest Expense | 0.00 | 81.00K | 973.00K | 1.44M | 955.17K | 980.38K | 872.93K | 1.06M | 1.26M | 1.01M | 475.30K | 2.58M | 2.50M | 1.59M |
| Depreciation & Amortization | 1.46M | 777.00K | 692.00K | 550.00K | 250.56K | 109.44K | 116.45K | 155.71K | 211.95K | 377.26K | 426.18K | 416.97K | 354.89K | 266.22K |
| EBITDA | -20.99M | -15.58M | -12.75M | -4.79M | -4.33M | -5.07M | -6.18M | -6.85M | -6.97M | -3.13M | -6.16M | -2.70M | -5.46M | -7.60M |
| EBITDA Ratio | -87.62% | -75.80% | -78.19% | -37.30% | -38.64% | -69.87% | -84.05% | -123.63% | -158.07% | -217.95% | -168.19% | -61.81% | -145.70% | -279.09% |
| Operating Income | -22.45M | -16.33M | -13.37M | -6.22M | -4.59M | -5.25M | -6.34M | -7.49M | -8.97M | -5.32M | -7.47M | -3.13M | -5.92M | -9.52M |
| Operating Income Ratio | -93.70% | -79.47% | -82.05% | -48.48% | -40.95% | -71.37% | -85.86% | -130.25% | -195.34% | -147.61% | -190.17% | -61.87% | -155.09% | -356.45% |
| Total Other Income/Expenses | 357.00K | -103.00K | -1.04M | -562.00K | -945.79K | -915.70K | -831.52K | -581.16K | 524.86K | 795.89K | 388.50K | -2.58M | -2.39M | 61.06K |
| Income Before Tax | -22.09M | -16.44M | -14.41M | -6.78M | -5.54M | -6.16M | -7.17M | -8.07M | -8.45M | -4.52M | -7.09M | -5.71M | -8.31M | -9.45M |
| Income Before Tax Ratio | -92.21% | -79.97% | -88.41% | -52.86% | -49.39% | -83.82% | -97.12% | -140.36% | -183.91% | -125.53% | -180.29% | -112.83% | -217.68% | -354.16% |
| Income Tax Expense | 0.00 | 103.00K | 910.00K | 2.33M | 964.22K | 64.68K | 889.61K | 1.28M | 1.49M | 2.43M | 912.90K | 2.17M | 2.50M | 1.59M |
| Net Income | -22.09M | -16.54M | -15.32M | -9.11M | -6.50M | -6.16M | -7.17M | -8.07M | -8.45M | -4.52M | -7.09M | -5.71M | -8.31M | -9.45M |
| Net Income Ratio | -92.21% | -80.47% | -93.99% | -71.00% | -57.98% | -83.82% | -97.12% | -140.36% | -183.91% | -125.53% | -180.29% | -112.83% | -217.68% | -354.16% |
| EPS | -0.90 | -0.68 | -0.74 | -0.57 | -0.49 | -0.56 | -0.93 | -2.93 | -4.48 | -3.06 | -4.95 | -5.65 | -20.73 | -23.76 |
| EPS Diluted | -0.90 | -0.68 | -0.74 | -0.57 | -0.49 | -0.56 | -0.93 | -2.93 | -4.48 | -3.06 | -4.95 | -5.65 | -20.73 | -23.76 |
| Weighted Avg Shares Out | 24.61M | 24.18M | 20.73M | 15.85M | 13.16M | 10.93M | 7.74M | 2.75M | 1.88M | 1.48M | 1.43M | 1.01M | 401.03K | 397.98K |
| Weighted Avg Shares Out (Dil) | 24.61M | 24.18M | 20.73M | 15.85M | 13.16M | 10.93M | 7.74M | 2.75M | 1.88M | 1.48M | 1.43M | 1.01M | 401.03K | 397.98K |
ClearPoint Neuro: My Favorite Growth Stock
ClearPoint Neuro is an industry leader in providing tools for minimally invasive brain surgeries, neurosurgical laser therapy, and drug delivery to the brain. The company has established a deep moat by working with partners early in clinical work, making its...
ClearPoint Neuro, Inc. (CLPT) Q2 2024 Earnings Call Transcript
ClearPoint Neuro, Inc. (NASDAQ:CLPT ) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Joe Burnett - CEO Danilo D'Alessandro - CFO Conference Call Participants Frank Takkinen - Lake Street Capital Kyle Bauser - B. Riley...
ClearPoint Neuro, Inc. (CLPT) Reports Q2 Loss, Tops Revenue Estimates
ClearPoint Neuro, Inc. (CLPT) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.29 per share a year ago.
ClearPoint Neuro, Inc. (CLPT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
ClearPoint Neuro (CLPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The 3 Best Brain-Computer Interface Stocks to Buy Now
Brain-computer interface (BCI) technology creates a direct link between the brain's electrical activity and a digital device. This connection can bring a vast range of benefits in assisting, augmenting and repairing human cognitive functions.
ClearPoint Neuro to Announce Second Quarter 2024 Results August 7, 2024
SOLANA BEACH, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results...
7 Growth Stocks That Could 5X in 5 Years
Growth stocks have been on a wild ride for the past few years. The pandemic sent many soaring to unbelievable heights.
Strength Seen in ClearPoint Neuro (CLPT): Can Its 16.9% Jump Turn into More Strength?
ClearPoint Neuro (CLPT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
ClearPoint Neuro: Solid Progress Still Not Reflected In The Share Price
ClearPoint Neuro's business continues to perform well despite the stock struggling. The drug delivery business is thriving, which should be aided by maturing partner programs and the introduction of new services in coming years. The full market release of ClearPoint's...
ClearPoint Neuro Congratulates Partner Aspen Neuroscience on Use of the ClearPoint® Navigation System for All Enrolled Patients in ASPIRO Clinical Trial
SOLANA BEACH, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today congratulates its partner Aspen Neuroscience, Inc. on...
Source: https://incomestatements.info
Category: Stock Reports